SABS
SAB Biotherapeutics, Inc.
Set alert
- YTD
- -10.43%
- 1 year
- +11.30%
- Open
- 3.20
- Prev close
- 3.23
- Mkt cap
- 304.80M
- Vol
- 741.05K
- Avg vol
- 536.84K
- EPS
- -1.29
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.11
- High
- 3.37
- Forward P/E
- -1.56
- Beta
- 0.64
- Short ratio
- 1.22
- Inst. own
- 34.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 3.29
- 200-d avg
- 3.35
- 1y target
- 12.40
Key statistics
- Market cap
- 39.50M
- Enterprise value
- 17.04M
- Trailing P/E
- 0.00
- Forward P/E
- -1.56
- PEG ratio
- 0.00
- Price / sales
- 26.11
- Price / book
- 1.07
- EPS (TTM)
- -6.30
- Beta
- 0.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.51M
- Revenue growth
- 0.00%
- Free cash flow
- -26.31M
- Total cash
- 30.40M
- Total debt
- 4.52M
- Return on equity
- -174.73%
- Shares outstanding
- 9.23M
- Short % of float
- 1.41%
- 50-day average
- 3.29
- 200-day average
- 3.35
Analyst view
Consensus: none
- Target (low)
- 6.00
- Target (mean)
- 12.40
- Target (high)
- 25.00
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -1.21.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -1.07 | -1.12 | -0.05 | -4.67% |
| Aug 8, 2024 | Jun 1, 2024 | -1.13 | -0.79 | +0.34 | +30.09% |
| Aug 8, 2024 | Jun 1, 2024 | -1.13 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.98 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.98 | -0.54 | +0.44 | +44.90% |
| Apr 1, 2024 | Dec 1, 2023 | -0.64 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 9, 2024 | Craig-Hallum | init | — | Buy |
| Sep 12, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Sep 9, 2024 | Chardan Capital | main | Buy | Buy |
| Aug 28, 2024 | Oppenheimer | init | — | Outperform |
| Aug 12, 2024 | Chardan Capital | main | Buy | Buy |
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sabbiotherapeutics.com
News
- SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
- SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform
- SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
- FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes
- SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
- SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
- SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Rated “Moderate Buy” by Sell-Side Analysts
- SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
- SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- SAB BIO to Participate in Upcoming Investor Conferences
Your note
Sign in to keep a note on SABS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ELLIAS HELEN K | Director | Conversion of Exercise of derivative security | Nov 23, 2023 | 0 |
| KING MICHAEL | Chief Financial Officer | Purchase | Nov 29, 2023 | 5,000 |
| KROPOTOVA ALEXANDRA | Officer | Stock Award(Grant) | Mar 13, 2023 | 275,000 |
| MOIN ANDREW D. | Director | Conversion of Exercise of derivative security | Nov 23, 2023 | 0 |
| REICH SAMUEL J. | Officer and Director | Purchase | Nov 28, 2023 | 766,699 |
| SESSA CAPITAL MASTER, L.P. | Director | Conversion of Exercise of derivative security | Nov 23, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 9.94% | 917,826 | 3.93M | Sep 29, 2024 |
| RTW Investments LP | 6.88% | 635,276 | 2.72M | Sep 29, 2024 |
| Marshall Wace LLP | 4.98% | 459,168 | 1.97M | Sep 29, 2024 |
| Sessa Capital IM, L.P. | 4.97% | 458,457 | 1.96M | Sep 29, 2024 |
| Vanguard Group Inc | 2.99% | 276,336 | 1.18M | Sep 29, 2024 |
| HB Wealth Management, LLC | 1.18% | 108,600 | 464.81K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.52% | 232,567 | 995.39K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.46% | 42,636 | 182.48K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 41,315 | 176.83K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.16% | 14,370 | 61.50K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 12,940 | 55.38K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 9,834 | 42.09K | Oct 30, 2024 |